Presentations 2023

Conference on Retroviruses and Opportunistic Infections (CROI 2023), Seattle, Washington, 19-22 February 2023

Oral presentation:

  • Page-B score to estimate the hepatocellular carcinoma risk in people with HIV and HBV by Bernard Surial on behalf of the Swiss HIV Cohort Study, ATHENA Observational Cohort Study, EuroSIDA and ANRS CO3 AquitaineCohort. PRESENTATION
     

Poster presentation:

  • Trends in mortality in people living with HIV in an international cohort (RESPOND) presented by Erich Tusch on behalf of the RESPOND Study Group. POSTER and PRESENTATION
     
  • Chronic liver inflammation and use of contemporary ART among persons living with HIV presented by Ashley Roen on behalf of the RESPOND Study Group. POSTER
     

 

IWHOD 2023, Athens, Greece, 23-25 March 2023

Oral presentation:

  • Association between changes in body mass index and risk of hypertension and dyslipidaemia in people treated with integrase inhibitors and tenofovir alafenamide versus other contemporary regimens presented by Dathan Byonanebye on behalf of the RESPOND Study Group. PRESENTATION
     

Poster presentation:

  • Longitudinal CD4:CD8 ratio and CD8 counts and risk of AIDS and non-AIDS defining malignancies in antiretroviral treated people with HIV: The RESPOND cohort consortium presented by Frédérique Chammartin on behalf of the RESPOND Study Group. POSTER
     
  • Disruptions in testing and treatment services for hepatitis C virus during the SARS-CoV-2 epidemic among individuals with HIV susceptible for HCV reinfection: results from the EuroSIDA study presented by Anders Boyd on behalf of the EuroSIDA Study Group. POSTER
     
  • Temporal trends in the HIV care cascade across Europe between 2016-2020: Impact of COVID-19 presented by Olga Fursa on behalf of the EuroSIDA Study Group. POSTER
     

 

Asia-Pacific AIDS & Co-Infections Conference (APACC), Singapore 8-10 June 2023

Poster presentation:

  • Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes presented by Dhanushi Rupasignhe on behalf of the RESPOND Study Group. POSTER

 

12th IAS Conference on HIV Science, Brisbane, Australia, 23-26 July 2023

Oral presentations:

  • Integrase strand inhibitors (INSTI) related changes in BMI and risk of diabetes presented by Dhanushi Rupasignhe on behalf of the RESPOND Study Group. PRESENTATION
  • Impact of INSTI and TAF-related DMI changes and risk on hypertension and dyslipidemia in RESPOND presented by Dathan Byonanebye on behalf of the RESPOND Study Group. PRESENTATION
  •  

19th European AIDS Conference (EACS), Warsaw, Poland. 18-21 October 2023

Oral presentations:

  • Modifiable risk factors and their population attributable fractions for TB in People with HIV across Europe presented by Christian Kraef on behalf of the RESPOND Study Group. PRESENTATION
  •  
  • Effect of ART, immunological-virological status and prior tuberculosis on mortality among people with HIV in Europe presented by Erich Tusch on behalf of the EuroSIDA Study Group. PRESENTATION
  •  
  • Temporal trends and impact of COVID-19 on the HIV cascade of care across Europe between 2016-2021 presented by Lars Peters (on behalf of Olga Fursa) on behalf of the EuroSIDA Study Group. PRESENTATION
  •  
  • Disruptions in testing and treatment services for hepatitis C virus during the SARS-CoV-2 epidemic among individuals with HIV susceptible for HCV reinfection: results from the EuroSIDA study presented by Anders Boyd on the behalf of EuroSIDA Study Group. PRESENTATION Winner of EACS Rapid Abstract Award!


Poster presentation:

  • Differences in integrated assessment and management of non-communicable diseases (NCDs) for people with HIV across the WHO European Region by Christian Kraef on behalf of EuroSIDA Study Group. POSTER
 

25th International Workshop on Long-term Complications of HIV and SARS-CoV-2, Washington D.C., USA, 15th-16th December 2023

Oral presentation:

  • Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021: A Multinational Cohort Collaboration will be presented by Nadine Jaschinski on behalf of the RESPOND Study Group.